Table 1.

Correlation of miR-3607 expression with clinicopathological parameters of patients with prostate cancer

TotalRelative miR-3607 expression
Clinicopathological parameteran (%)LowNo changeHighP
Age, y
 404/100 (4)3/4 (75)1/4 (25)
 5034/100 (34)21/34 (62)6/34 (18)7/34 (20)P = 0.5065
 6047/100 (47)29/47 (62)9/47 (19)9/47 (19)
 7014/100 (14)9/14 (64)5/14 (36)
Gleason score
 6 (3+3)48/100 (48)26/48 (54)10/48 (21)12/48 (25)
 7 (3+4)29/100 (29)16/29 (55)4/29 (14)9/29 (31)P = 0.0173b
 7 (4+3)12/100 (12)11/12 (92)1/12 (8)
 8–109/100 (9)8/9 (89)1/9 (11)
Pathologic stage
 pT268/100 (68)37/68 (54)14/68 (21)17/68 (25)
 pT319/100 (19)15/19 (79)1/19 (5)3/19 (16)P = 0.0360b
 pT41/100 (1)1/1 (100)
PSA levels
 ≤4.7 (median)31/100 (31)10/31 (32)11/31 (36)10/31 (32)P = 0.0001b
 >4.7 (Median)63/100 (63)47/63 (75)4/63 (6)12/63 (19)
Biochemical recurrence
 Yes31/100 (31)22/31(71)2/31 (6)7/31 (23)P = 0.2381
 No63/100 (63)36/63 (57)12/63 (19)15/63 (24)
  • aCorrelation of miR-3607 expression with clinicopathological characteristics of patients with prostate cancer including age, Gleason score, pathologic stage, PSA levels, and biochemical recurrence was examined.

  • bP < 0.05.